Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georges M Gharabawi

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
The Journal of Clinical Psychiatry|September 16, 2004
Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidoneMichael G Aman, Georges M Gharabawi,
The American Journal of Psychiatry|May 2, 2006
New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidolGeorges M Gharabawi, Cynthia A Bossie, Young Zhu
Child and Adolescent Psychiatry and Mental Health|August 9, 2007
Evaluating movement disorders in pediatric patients receiving risperidone: a comparison of spontaneous reports and research criteria for TDGahan J Pandina, Cynthia A Bossie, Young Zhu, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|June 16, 2004
Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidoneRobert A Lasser, Cynthia A Bossie, Georges M Gharabawi, et al.
Schizophrenia Research|May 24, 2005
Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injectionRobert A Lasser, Cynthia A Bossie, Georges M Gharabawi, et al.
The International Journal of Neuropsychopharmacology|April 5, 2005
Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trialRobert A Lasser, Cynthia A Bossie, Georges M Gharabawi, et al.
International Clinical Psychopharmacology|May 12, 2006
Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidoneGeorges M Gharabawi, Robert A Lasser, Cynthia A Bossie, et al.
Schizophrenia Research|May 26, 2005
An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term studyGeorges M Gharabawi, Cynthia A Bossie, Young Zhu, et al.
Schizophrenia Research|May 26, 2005
Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesiaGeorges M Gharabawi, Cynthia A Bossie, Robert A Lasser, et al.
Current Medical Research and Opinion|October 4, 2007
Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorderMarcia F T Rupnow, Andrew Greenspan, Georges M Gharabawi, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
The Journal of Clinical Psychiatry|September 16, 2004
Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidoneMichael G Aman, Georges M Gharabawi,
The American Journal of Psychiatry|May 2, 2006
New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidolGeorges M Gharabawi, Cynthia A Bossie, Young Zhu
Child and Adolescent Psychiatry and Mental Health|August 9, 2007
Evaluating movement disorders in pediatric patients receiving risperidone: a comparison of spontaneous reports and research criteria for TDGahan J Pandina, Cynthia A Bossie, Young Zhu, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|June 16, 2004
Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidoneRobert A Lasser, Cynthia A Bossie, Georges M Gharabawi, et al.
Schizophrenia Research|May 24, 2005
Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injectionRobert A Lasser, Cynthia A Bossie, Georges M Gharabawi, et al.
The International Journal of Neuropsychopharmacology|April 5, 2005
Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trialRobert A Lasser, Cynthia A Bossie, Georges M Gharabawi, et al.
International Clinical Psychopharmacology|May 12, 2006
Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidoneGeorges M Gharabawi, Robert A Lasser, Cynthia A Bossie, et al.
Schizophrenia Research|May 26, 2005
An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term studyGeorges M Gharabawi, Cynthia A Bossie, Young Zhu, et al.
Schizophrenia Research|May 26, 2005
Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesiaGeorges M Gharabawi, Cynthia A Bossie, Robert A Lasser, et al.
Current Medical Research and Opinion|October 4, 2007
Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorderMarcia F T Rupnow, Andrew Greenspan, Georges M Gharabawi, et al.
Pageof 3